Centrally acting antihypertensive agent Ketanserin potential role in delirium management: A review.

Firas Hasan Bazzari

Abstract


Abstract:

Delirium is a psychiatric disorder that is well known for being a clinical challenge due to its complex pathophysiology and the wide range of risk factors associated with it. Up to this date, no medical agent is approved by the Food and Drug Administration (FDA) for the treatment of delirium; despite the fact that, a number of clinical guidelines and protocols have recommended the use of some drugs in the management of delirium. Delirium risk factors; predisposing, hospital and acute underlying disease factors, are considered critical points in understanding delirium mechanism. Furthermore, several pathophysiological hypotheses; neurotransmitters imbalance hypothesis, inflammatory hypothesis and structural defects hypothesis, were introduced to explain delirium pathogenesis. Nevertheless, the current evidence is mainly based on and validates the neurotransmitters imbalance theory, since neurotransmitters form the molecular basis of the central nervous system and can be affected by any change occurs in the brain normal conditions. Moreover, pharmacological options introduced as delirium therapies with relative efficacy are mainly based on the neurotransmitters imbalance theory. Ketanserin is a centrally acting antihypertensive agent that has been in the market for over 30 years from now; thus, safety profile is well established. Ketanserin special and unique mechanism of action by inhibiting a wide range of central nervous system receptors; serotonergic (5-HT1D, 5-HT2B, 5-HT2C, 5-HT6), dopaminergic (D1, D2) and adrenergic (α1, α2) receptors, theoretically seems to match with the pathophysiological hypothesis of neurotransmitters imbalance. Moreover, ketanserin might also serve as an empirical therapy for delirium, when the cause of delirium; other than the underlying medical condition, is not determined and an immediate intervention is needed. As it antagonizes almost all the receptors thought to be associated with delirium. Nevertheless, up to this point, it is still a theoretical assumption about the potential role of ketanserin as a pharmacological option in delirium management that needs further investigations to confirm its efficacy.                 


Keywords


Delirium; Ketanserin; Management; Treatments

Full Text:

PDF

References


References List:

Lipowski Z. Delirium (acute confusional states). JAMA. 1987; 258(13): p. 1789-1792.

Stango D, Gibson C, Breitbart W. The delirium subtypes: a review of prevalence, phenomenology, pathophysiology, and treatment response. Palliative & supportive care. 2004; 2(2): p. 171-179.

Rockwood K. Causes of delirium. Psychiatry. 2008; 7(1): p. 39-41.

Rudolph JL, Archambault E, Budd MA. Delirium: Risk Identification, Mitigation, and Intervention. Practical Psychology in Medical Rehabilitation. 2017;: p. 235-239.

Otani VHO, Otani TZDS, Freirias A, Calfat ELDB, Aoki PS, Cordeiro Q, et al. Misidentification of mental health symptoms in presence of organic diseases and delirium during psychiatric liaison consulting. nternational Journal of Psychiatry in Clinical Practice. 2017;: p. 1-6.

Anand A, MacLullich AM. Delirium in hospitalized older adults. Medicine. 2017; 15(1): p. 46-50.

Brummel N, Girard T. Preventing delirium in the intensive care unit. Critical care clinics. 2013; 29(1): p. 51-65.

Fong T, Tulebaev S, Inouye S. Delirium in elderly adults: diagnosis, prevention and treatment. Nature Reviews Neurology. 2009; 5(4): p. 210-220.

FDA. FDA. [Online].; 2017 [cited 2017 March 20. Available from: HYPERLINK "https://www.fda.gov/Drugs/default.htm" https://www.fda.gov/Drugs/default.htm .

Fosnight S. DELIRIUM IN THE ELDERLY. Geriatrics. 2011;: p. 73-96.

Barr J, Fraser GL, Puntillo K, Ely EW, Gélinas C, Dasta JF, et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Critical Care Medicine. 2013; 41(1): p. 263-306.

Olivier B, Van Wijngaarden I, Soudijn W. Serotonin receptors and their ligands. Elsevier. 1997; 27.

Fleet J, Ernst T. Guy's and St Thomas. [Online].; 2011 [cited 2017 April 2. Available from: HYPERLINK "http://www.guysandstthomas.nhs.uk/resources/our-services/acute-medicine-gi-surgery/elderly-care/delirium-adult-inpatients.pdf" http://www.guysandstthomas.nhs.uk/resources/our-services/acute-medicine-gi-surgery/elderly-care/delirium-adult-inpatients.pdf .

McNicoll L, Pisani MA, Zhang Y, Ely E, Siegel MD, Inouye SK. Delirium in the intensive care unit: occurrence and clinical course in older patients. Journal of the American Geriatrics Society. 2003; 51(5): p. 591-598.

Hsieh SJ, Shum M, Lee AN, Hasselmark F, Gong MN. Cigarette smoking as a risk factor for delirium in hospitalized and intensive care unit patients. A systematic review. Annals of the American Thoracic Society. 2013; 10(5): p. 496-503.

Monte R, Rabuñal R, Casariego E, Bal M, Pértega S. Risk factors for delirium tremens in patients with alcohol withdrawal syndrome in a hospital setting. European journal of internal medicine. 2009; 20(7): p. 690-694.

Tully P, Baker R, Winefield H, Turnbull D. Depression, anxiety disorders and Type D personality as risk factors for delirium after cardiac surgery. Australian and New Zealand Journal of Psychiatry. 2010; 44(11): p. 1005-1011.

Ouimet S, Kavanagh B, Gottfried S, Skrobik Y. Incidence, risk factors and consequences of ICU delirium. Intensive Care Medicine. 2007; 33(1): p. 66-73.

Canonico A, Light R, Pandharipande P, Laskowitz D. Apolipoprotein E4 polymorphism as a genetic predisposition to delirium in critically ill patients. Critical Care Medicine. 2007; 119(6): p. 737-754.

McCusker J, Cole M, Abrahamowicz M, Han L, Podoba JE, Ramman‐Haddad L. Environmental risk factors for delirium in hospitalized older people. Journal of the American Geriatrics Society. 2001; 49(10): p. 1327-1334.

Inouye S. Delirium in hospitalized older patients. Clinics in Geriatric Medicine. 1998; 14(4): p. 749-764.

Tune L, Egeli S. Acetylcholine and delirium. Dementia and geriatric cognitive disorders. 1999; 10(5): p. 342-344.

Ross C. CNS arousal systems: possible role in delirium. International Psychogeriatrics. 1991; 3(2): p. 353-371.

KIM JY, JUNG IK, Han C, CHO SH, Kim L, KIM SH, et al. Antipsychotics and dopamine transporter gene polymorphisms in delirium patients. Psychiatry and clinical neurosciences. 2005; 59(2): p. 183-188.

Mrzljak L, Goldman‐Rakic P. Acetylcholinesterase reactivity in the frontal cortex of human and monkey: Contribution of AChE‐rich pyramidal neurons. Journal of Comparative Neurology. 1992; 324(2): p. 261-281.

Van Der Mast R, Fekkes D. Serotonin and amino acids: partners in delirium pathophysiology? Seminars in clinical neuropsychiatry. 2000; 5(2): p. 125-131.

Knell AJ, Davidson AR, Williams R, Kantamaneni BD, Curzon G. Dopamine and serotonin metabolism in hepatic encephalopathy. Br Med J. 1974; 1(5907): p. 549-551.

Hshieh T, Fong TG, Marcantonio ER, Inouye S. Cholinergic Deficiency Hypothesis in Delirium: A Synthesis of Current Evidence. The Journals of Gerontology. 2008; 63(7): p. 764–772.

O’Donnell J, Zeppenfeld D, McConnell E, Pena S, Nedergaard M. Norepinephrine: a neuromodulator that boosts the function of multiple cell types to optimize CNS performance. Neurochemical research. 2012; 37(11): p. 2496-2512.

Petroff O. GABA and glutamate in the human brain. The Neuroscientist. 2002; 8(6): p. 562-573.

Ali S, Patel M, Jabeen S, Bailey R, Patel T, Shahid M. Insight into Delirium. Innovations in Clinical Neuroscience. 2011; 8(10): p. 25-34.

Ebersoldt M, Sharshar T, Annane D. Sepsis-associated delirium. Intensive care medicine. 2007; 33(6): p. 941-950.

Van Munster BC, Korevaar JC, Zwinderman AH, Levi M, Wiersinga WJ, De Rooij SE. Time‐course of cytokines during delirium in elderly patients with hip fractures. Journal of the American Geriatrics Society. 2008; 56(9): p. 1704-1709.

Soiza RL, Sharma V, Ferguson K, Shenkin SD, Seymour DG, MacLullich AM. Neuroimaging studies of delirium: a systematic review. Journal of psychosomatic research. 2008; 65(3): p. 239-248.

Nakamura A, Inada T, Kitao Y, Katayama Y. Association between catechol‐O‐methyltransferase (COMT) polymorphism and severe alcoholic withdrawal symptoms in male Japanese alcoholics. Addiction biology. 2001; 6(3): p. 233-238.

Davies D. Blood–brain barrier breakdown in septic encephalopathy and brain tumours. Journal of anatomy. 2002; 200(6): p. 639-646.

Mauersberger H. Long-term safety and efficacy of ketanserin in essential hypertension: ketanserin versus or in combination with metoprolol. Journal of hypertension. 1986; 4(1): p. 73-75.

Delaney J, Spevack D, Doddamani S, Ostfeld R. Clonidine-induced delirium. International journal of cardiology. 2006; 113(2): p. 276-278.

Richtand NM, Welge JA, Logue AD, Keck PE, Strakowski SM, McNamara RK. Dopamine and serotonin receptor binding and antipsychotic efficacy. Neuropsychopharmacology. 2007; 32(8): p. 1715-1726.

Sasaki Y, Matsuyama T, Inoue S, Sunami T, Inoue T, Denda K, et al. A prospective, open-label, flexible-dose study of quetiapine in the treatment of delirium. Journal of Clinical Psychiatry. 2003; 64(11): p. 1316-1321.

Meagher DJ. Regular review: Delirium: optimising management. BMJ: British Medical Journal. 2001; 322(7279): p. 144.

Rockwood K. The occurrence and duration of symptoms in elderly patients with delirium. Journal of Gerontology. 1993; 48(4): p. 162-166.




DOI: https://doi.org/10.23954/osj.v2i3.1142

Refbacks

  • There are currently no refbacks.